• Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact
Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer
  • Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact

News

 Nascent Biotech Announces Initial Dosing Underway in Phase 1 Human Trial for Primary and Metastatic Brain Cancer
0
By Nascent
In News, Science News
Posted March 31, 2021

Nascent Biotech Announces Initial Dosing Underway in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

SAN DIEGO, CA / ACCESSWIRE / March 31, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech,” “Nascent,” or the “Company”), a clinical-stage [...]

READ MORE
 BioPharma Journal: Why Nascent Biotech Inc (OTCMKTS:NBIO) is Worth a Close Look
0
By Nascent
In Corporate News, News
Posted March 26, 2021

BioPharma Journal: Why Nascent Biotech Inc (OTCMKTS:NBIO) is Worth a Close Look

Nascent Biotech Inc. (OTCMKTS:NBIO) is a clinical stage biopharmaceutical company with a number of potential drivers and catalysts in play. Today, we take a look at recent analysis and [...]

READ MORE
 Nascent Biotech Opens Phase 1 Human Trial to Evaluate Pritumumab as Treatment Option for Primary and Metastatic Brain Cancer
0
By Nascent
In News, Science News
Posted March 24, 2021

Nascent Biotech Opens Phase 1 Human Trial to Evaluate Pritumumab as Treatment Option for Primary and Metastatic Brain Cancer

SAN DIEGO, CA / ACCESSWIRE / March 24, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
 Nascent Biotech Earns US Patent for Crossing Blood-Brain Barrier
0
By Nascent
In News
Posted March 2, 2021

Nascent Biotech Earns US Patent for Crossing Blood-Brain Barrier

SAN DIEGO, CA / ACCESSWIRE / March 2, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
 Keeping SARS2 Out of the Cell
0
By Nascent
In Science News
Posted February 17, 2021

Keeping SARS2 Out of the Cell

A&S physicists are leading a team of researchers who are one of the first to pinpoint a novel method of using anti-vimentin antibodies to block cellular uptake of the coronavirus. As vaccines [...]

READ MORE
 Nascent Biotech Research Partner, Manhattan BioSolutions, to Present at the ACCESS CHINA Forum at the 2021 JPMorgan Healthcare Conference
0
By Nascent
In Corporate News, News, Press Releases
Posted January 19, 2021

Nascent Biotech Research Partner, Manhattan BioSolutions, to Present at the ACCESS CHINA Forum at the 2021 JPMorgan Healthcare Conference

SAN DIEGO, CA / ACCESSWIRE / January 19, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO). Nascent Biotech Research Partner, Manhattan BioSolutions (MABS), Inc. announced that it will be presenting at [...]

READ MORE
 Nascent Biotech Receives Full IND Clearance to Begin Phase I Human Trials for Brain Cancer
0
By Nascent
In Corporate News, News, Press Releases, Science News
Posted December 15, 2020

Nascent Biotech Receives Full IND Clearance to Begin Phase I Human Trials for Brain Cancer

SAN DIEGO, CA / ACCESSWIRE / December 15, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) On December 7, the Company received a letter from the US Food and Drug Administration (FDA) removing a partial [...]

READ MORE
 Nascent Biotech Announces Promising Covid-19 Invitro Study Results with Syracuse University Collaboration
0
By Nascent
In Corporate News, News, Press Releases, Science News
Posted October 20, 2020

Nascent Biotech Announces Promising Covid-19 Invitro Study Results with Syracuse University Collaboration

SAN DIEGO, CA / ACCESSWIRE / October 20, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech” or the “Company”) is pleased to announce that the Company has [...]

READ MORE
 Nascent Biotech Continues to Reduce Liabilities by Over $2.0 Million Dollars
0
By Nascent
In Corporate News, News, Press Releases
Posted October 1, 2020

Nascent Biotech Continues to Reduce Liabilities by Over $2.0 Million Dollars

SAN DIEGO, CA / ACCESSWIRE / October 1, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) Announced today that It has continued to reduce its liabilities through stock conversion and payment of accounts [...]

READ MORE
 Nascent Biotech Research Collaboration Partner, Manhattan BioSolutions, Receives Grant for Covid 19 Vaccine Studies
0
By Nascent
In Corporate News, News, Press Releases
Posted September 24, 2020

Nascent Biotech Research Collaboration Partner, Manhattan BioSolutions, Receives Grant for Covid 19 Vaccine Studies

SAN DIEGO, CA / ACCESSWIRE / September 23, 2020 / Nascent Biotech, Inc (OTCQB:NBIO), a biotechnology company pioneering innovative medicines to overcome difficult-to-treat cancers and viral [...]

READ MORE
1 2 3 4 5
page 1 of 5
© NASCENT BIOTECH, INC. ALL RIGHTS RESERVED.